Pear Therapeutics, Inc.
https://peartherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Pear Therapeutics, Inc.
News We're Watching: Abbott, Click, Otsuka, Prenosis Win FDA Approval; EU Health Data Space Proposal, And More
This week, Abbott, Click and Otsuka, Prenosis won the FDA nod respectively for an in vitro diagnostic to evaluate patients for concussion, the first prescription digital therapeutic to treat major depressive disorder and a software to predict sepsis. Also on the regulatory front, the FDA will now take 513(g)s forms via its eSTAR framework. In Europe, the debate of what personal information can be shared continues.
Updated: Pear Therapeutics PDTs Reborn In PursueCare, Supported By Pear's Ex-CEO
Pear Therapeutic’s PDTs have a new home at PursueCare thanks to $20m in series B funding led by Tr.X Capital, led by Pear's former CEO.
Better Therapeutics Plans Diabetes PDT Launch Following FDA De Novo Authorization
FDA authorized Better Therapeutics’ AspyreRx, formerly known as BT-001, a prescription-only digital therapeutic that provides cognitive behavioral therapy to adults with type 2 diabetes. The company plans to launch it in the fourth quarter of 2023.
Investor Eye: Sofinnova Partners Are Redefining And Disobeying The Venture Investment Commandments
Sofinnova Partners has played an important role in defining the medtech investment space for the past 50 years, helping bring to market a plethora of life-saving technologies, even when they appear, initially, to be risky.
Company Information
- Industry
- Digital Health
- Medical Devices
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice